Tumor Treating Field (TTF) Therapy
Defines Blue KC's payment and coverage guidance for Tumor Treating Field (TTF) therapy (also called alternating electric field therapy) for glioblastoma and malignant pleural mesothelioma, and indicates impacted provider types and lines of business.
Policy references MCG A-0930 Alternating Electric Field Therapy for medical necessity indications.
Coverage and Medical Necessity
Coverage and medical necessity
Medical necessity and coverage decisions are governed by the external MCG guideline; providers should consult MCG A-0930 for indication-specific criteria.
ALL of the following
- Medical necessity and coverage determinations for Tumor Treating Field (alternating electric field) therapy are governed by MCG A-0930 Alternating Electric Field Therapy; this policy defers to that guideline for indication-specific criteria.
- Providers seeking coverage or prior authorization should reference MCG A-0930 for the clinical criteria that must be met for medical necessity determinations.
- Coding examples provided in this policy (e.g., 77299, A4555, E0766) are illustrative; they do not replace the clinical criteria and coverage determinations in MCG A-0930.
Coding References
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.